← Leaderboards
Dirk P Dittmer
Univ Of North Carolina Chapel Hill
$32,603,888
Attributed
$39,594,170
Total exposure
29
Grants
23
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.3M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$46,009,072 · 31
By mechanism
R01$26,056,298 · 8
P01$7,733,637 · 8
U54$6,848,576 · 2
R21$2,340,614 · 6
U19$1,174,069 · 1
P20$1,028,790 · 2
Top collaborators
- Blossom A Damania40 shared
- Carla J Chibwesha7 shared
- Yuri Fedoriw7 shared
- Paul Ruff7 shared
- Jacqueline Huwa4 shared
- Hannock Mukoma Tweya3 shared
- Mwapatsa Mipando2 shared
- Nyengo Mkandawire2 shared
Most similar at Univ Of North Carolina Chapel Hill
Same institution · by research overlap
- Catherine Fahey$147,667
- Taylor Joel Richard Penke$84,191
- Ian J Davis$7,130,869
- Kathleen M Caron$16,068,293
- Yuri Fedoriw$2,581,863
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsHuman Herpesvirus 8ViralCellsKaposi SarcomaFundingMolecularAcquired Immunodeficiency SyndromeResponseLymphomaGenetic TranscriptionResearch PersonnelIn VivoMicrornasTumorMouse ModelVirusTumorigenesisPersonsBaseClinical TrialsBiologyAids/Hiv ProblemPharmaceutical Preparations
Grant awards (148)
ART Modulation of Viral Pathogenesis$1,579,497
R01 · FY2025 · DE · contact PI
Targeted Therapies for HIV-Associated Kaposi Sarcoma and Lymphoma$400,139
R01 · FY2025 · CA · contact PI
Modulation of tumorigenesis by viral exosomes$347,154
P01 · FY2025 · CA · contact PI
Concentration and single virion analysis of the virome$233,250
U01 · FY2025 · DE · contact PI
Vironomics and Biostatistics Core$225,347
P01 · FY2025 · CA · contact PI
Replication studies for Kaposi Sarcoma mice$77,750
R01 · FY2025 · CA · contact PI
Virology Research Program$46,265
P30 · FY2025 · CA · contact PI
Innovations for screening and prognosis in HIV+ cancers including Kaposi sarcoma, cervical cancer, and lymphoma in Malawi and South Africa$1,094,228
U54 · FY2024 · CA
PQ6: Transgenic Mouse Model for Kaposi Sarcoma$492,087
R01 · FY2024 · CA · contact PI
Targeted Therapies for HIV-Associated Kaposi Sarcoma and Lymphoma$400,103
R01 · FY2024 · CA · contact PI
Modulation of tumorigenesis by viral exosomes$347,154
P01 · FY2024 · CA · contact PI
Concentration and single virion analysis of the virome$233,250
U01 · FY2024 · DE · contact PI
Vironomics and Biostatistics Core$225,347
P01 · FY2024 · CA · contact PI
Project 2: Clinical and molecular determinants of HIV-associated Kaposi Sarcoma progression under local standard-of-care therapy in Malawi and South Africa$184,511
U54 · FY2024 · CA · contact PI
Virology Research Program$40,560
P30 · FY2024 · CA · contact PI
Innovations for screening and prognosis in HIV+ cancers including Kaposi sarcoma, cervical cancer, and lymphoma in Malawi and South Africa$1,097,066
U54 · FY2023 · CA
Mechanisms of KSHV Transmission$583,738
R01 · FY2023 · CA · contact PI
PQ6: Transgenic Mouse Model for Kaposi Sarcoma$507,637
R01 · FY2023 · CA · contact PI
Targeted Therapies for HIV-Associated Kaposi Sarcoma and Lymphoma$400,103
R01 · FY2023 · CA · contact PI
ART Modulation of Viral Pathogenesis$369,313
R01 · FY2023 · DE · contact PI
Modulation of tumorigenesis by viral exosomes$347,154
P01 · FY2023 · CA · contact PI
Vironomics and Biostatistics Core$225,347
P01 · FY2023 · CA · contact PI
Project 2: Clinical and molecular determinants of HIV-associated Kaposi Sarcoma progression under local standard-of-care therapy in Malawi and South Africa$184,511
U54 · FY2023 · CA · contact PI
Virology Research Program$45,065
P30 · FY2023 · CA · contact PI
Innovations for screening and prognosis in HIV+ cancers including Kaposi sarcoma, cervical cancer, and lymphoma in Malawi and South Africa$1,101,859
U54 · FY2022 · CA
Mechanisms of KSHV Transmission$583,738
R01 · FY2022 · CA · contact PI
PQ6: Transgenic Mouse Model for Kaposi Sarcoma$515,412
R01 · FY2022 · CA · contact PI
Targeted Therapies for HIV-Associated Kaposi Sarcoma and Lymphoma$400,137
R01 · FY2022 · CA · contact PI
Impact of HIV on the Tumor Microenvironment$387,192
R01 · FY2022 · CA · contact PI
ART Modulation of Viral Pathogenesis$369,313
R01 · FY2022 · DE · contact PI
Modulation of tumorigenesis by viral exosomes$347,154
P01 · FY2022 · CA · contact PI
Vironomics and Biostatistics Core$225,347
P01 · FY2022 · CA · contact PI
Project 2: Clinical and molecular determinants of HIV-associated Kaposi Sarcoma progression under local standard-of-care therapy in Malawi and South Africa$184,511
U54 · FY2022 · CA · contact PI
Performance of different sample types for high-risk human papillomavirus testing and genotyping for the detection of high grade cervical intraepithelial neoplasia$125,000
U54 · FY2022 · CA
Virology Research Program$45,065
P30 · FY2022 · CA · contact PI
Innovations for screening and prognosis in HIV+ cancers including Kaposi sarcoma, cervical cancer, and lymphoma in Malawi and South Africa$1,109,032
U54 · FY2021 · CA
Mechanisms of KSHV Transmission$583,738
R01 · FY2021 · CA · contact PI
PQ6: Transgenic Mouse Model for Kaposi Sarcoma$521,632
R01 · FY2021 · CA
Impact of HIV on the Tumor Microenvironment$387,192
R01 · FY2021 · CA · contact PI
ART Modulation of Viral Pathogenesis$369,313
R01 · FY2021 · DE · contact PI
The road to recovery: An assessment of patient-reported quality of life among cancer survivors in Malawi.$190,625
U54 · FY2021 · CA
Project 2: Clinical and molecular determinants of HIV-associated Kaposi Sarcoma progression under local standard-of-care therapy in Malawi and South Africa$184,512
U54 · FY2021 · CA · contact PI
Virology Research Program$45,065
P30 · FY2021 · CA · contact PI
Innovations for screening and prognosis in HIV+ cancers including Kaposi sarcoma, cervical cancer, and lymphoma in Malawi and South Africa$1,180,460
U54 · FY2020 · CA
Mechanisms of KSHV Transmission$550,989
R01 · FY2020 · CA · contact PI
PQ6: Transgenic Mouse Model for Kaposi Sarcoma$529,632
R01 · FY2020 · CA
Impact of HIV on the Tumor Microenvironment$387,192
R01 · FY2020 · CA · contact PI
ART Modulation of Viral Pathogenesis$369,313
R01 · FY2020 · DE · contact PI
Targeted Therapies for HIV-Associated Kaposi Sarcoma and Lymphoma$342,759
R01 · FY2020 · CA · contact PI
Project 4 - Study of KSHV Carcinogenesis$281,390
P01 · FY2020 · CA · contact PI
Core B - Virogenomics & Biostatistics Core$246,815
P01 · FY2020 · CA · contact PI
Project 2: Clinical and molecular determinants of HIV-associated Kaposi Sarcoma progression under local standard-of-care therapy in Malawi and South Africa$212,261
U54 · FY2020 · CA · contact PI
Mechanisms of KSHV Transmission$527,310
R01 · FY2019 · CA · contact PI
Impact of HIV on the Tumor Microenvironment$375,575
R01 · FY2019 · CA · contact PI
ART Modulation of Viral Pathogenesis$369,313
R01 · FY2019 · DE · contact PI
HIV and substances of abuse influence exosomes and endothelial cell function$367,675
R01 · FY2019 · DA · contact PI
Targeted Therapies for HIV-Associated Kaposi Sarcoma and Lymphoma$342,759
R01 · FY2019 · CA · contact PI
Project 4 - Study of KSHV Carcinogenesis$273,628
P01 · FY2019 · CA · contact PI
Core B - Virogenomics & Biostatistics Core$239,051
P01 · FY2019 · CA · contact PI
Core B - Virogenomics & Biostatistics Core$9,134
P01 · FY2019 · CA · contact PI
Project 4 - Study of KSHV Carcinogenesis$9,133
P01 · FY2019 · CA · contact PI
Impact of HIV on the Tumor Microenvironment$466,495
R01 · FY2018 · CA · contact PI
HIV and substances of abuse influence exosomes and endothelial cell function$367,675
R01 · FY2018 · DA · contact PI
Targeted Therapies for HIV-Associated Kaposi Sarcoma and Lymphoma$342,759
R01 · FY2018 · CA · contact PI
Project 4 - Study of KSHV Carcinogenesis$281,393
P01 · FY2018 · CA · contact PI
Core B - Virogenomics & Biostatistics Core$246,818
P01 · FY2018 · CA · contact PI
Core B - Virogenomics & Biostatistics Core$9,134
P01 · FY2018 · CA · contact PI
Project 4 - Study of KSHV Carcinogenesis$9,133
P01 · FY2018 · CA · contact PI
Targeting the epigenome of gammaherpesviruses in oral disease$394,639
R01 · FY2017 · DE
Targeting the epigenome of gammaherpesviruses in oral disease$378,255
R01 · FY2017 · DE
ART Modulation of Viral Pathogenesis$377,837
R01 · FY2017 · DE · contact PI
HIV and substances of abuse influence exosomes and endothelial cell function$370,472
R01 · FY2017 · DA · contact PI
Data Management and Resource Dissemination Core$355,749
U19 · FY2017 · AI · contact PI
Targeted Therapies for HIV-Associated Kaposi Sarcoma and Lymphoma$342,759
R01 · FY2017 · CA · contact PI
Project 4 - Study of KSHV Carcinogenesis$303,916
P01 · FY2017 · CA · contact PI
Planning for a National Non-Communicable Disease Center of Research Excellence$251,816
P20 · FY2017 · CA · contact PI
Targeted Therapies for HIV-Associated Kaposi Sarcoma and Lymphoma$236,852
R01 · FY2017 · CA · contact PI
Core B - Virogenomics & Biostatistics Core$234,768
P01 · FY2017 · CA · contact PI
Targeting the epigenome of gammaherpesviruses in oral disease$378,255
R01 · FY2016 · DE
ART Modulation of Viral Pathogenesis$377,837
R01 · FY2016 · DE · contact PI
HIV and substances of abuse influence exosomes and endothelial cell function$368,240
R01 · FY2016 · DA · contact PI
Targeted Therapies for HIV-Associated Kaposi Sarcoma and Lymphoma$342,759
R01 · FY2016 · CA · contact PI
Project 4 - Study of KSHV Carcinogenesis$303,998
P01 · FY2016 · CA · contact PI
Planning for a National Non-Communicable Disease Center of Research Excellence$264,816
P20 · FY2016 · CA
Core B - Virogenomics & Biostatistics Core$234,830
P01 · FY2016 · CA · contact PI
Data Management and Resource Dissemination Core$210,223
U19 · FY2016 · AI · contact PI
Origin and Lineage of Differentiation of Kaposi's Sarcoma$173,323
R21 · FY2016 · CA
HIV and substances of abuse influence exosomes and endothelial cell function$391,959
R01 · FY2015 · DA · contact PI
Targeting the epigenome of gammaherpesviruses in oral disease$378,255
R01 · FY2015 · DE
ART Modulation of Viral Pathogenesis$377,837
R01 · FY2015 · DE · contact PI
Targeted Therapies for HIV-Associated Kaposi Sarcoma and Lymphoma$305,754
R01 · FY2015 · CA · contact PI
Cellular Reprogramming by KSHV Latent Genes and miRNAs$291,273
P01 · FY2015 · CA · contact PI
Virogenomics Core$270,710
P01 · FY2015 · CA · contact PI
Data Management and Resource Dissemination Core$195,118
U19 · FY2015 · AI · contact PI
Origin and Lineage of Differentiation of Kaposi's Sarcoma$172,916
R21 · FY2015 · CA
Targeting the epigenome of gammaherpesviruses in oral disease$378,255
R01 · FY2014 · DE
ART Modulation of Viral Pathogenesis$377,837
R01 · FY2014 · DE · contact PI
Targeted Therapies for HIV-Associated Kaposi Sarcoma and Lymphoma$296,581
R01 · FY2014 · CA · contact PI
Cellular Reprogramming by KSHV Latent Genes and miRNAs$283,421
P01 · FY2014 · CA · contact PI
Virogenomics Core$262,859
P01 · FY2014 · CA · contact PI
Regulation of the KSHV Latent Promoter$227,369
R01 · FY2014 · CA · contact PI
Data Management and Resource Dissemination Core$219,442
U19 · FY2014 · AI · contact PI
Pathobiology and Clinical Profile of HIV-Associated Cancers in India and the West$204,706
R21 · FY2014 · CA · contact PI
(PQD2) Why is Endemic Burkitt Lymphoma Curable with Single Agent Chemotherapy?$192,409
R21 · FY2014 · CA · contact PI
Targeting the epigenome of gammaherpesviruses in oral disease$378,255
R01 · FY2013 · DE
ART Modulation of Viral Pathogenesis$364,837
R01 · FY2013 · DE · contact PI
Targeted Therapies for HIV-Associated Kaposi Sarcoma and Lymphoma$287,409
R01 · FY2013 · CA · contact PI
Cellular Reprogramming by KSHV Latent Genes and miRNAs$273,796
P01 · FY2013 · CA · contact PI
Virogenomics Core$254,467
P01 · FY2013 · CA · contact PI
Regulation of the KSHV Latent Promoter$220,337
R01 · FY2013 · CA · contact PI
Pathobiology and Clinical Profile of HIV-Associated Cancers in India and the West$206,901
R21 · FY2013 · CA · contact PI
Data Management and Resource Dissemination Core$193,537
U19 · FY2013 · AI · contact PI
(PQD2) Why is Endemic Burkitt Lymphoma Curable with Single Agent Chemotherapy?$165,300
R21 · FY2013 · CA · contact PI
Targeted Therapies for HIV-Associated Kaposi Sarcoma and Lymphoma$305,754
R01 · FY2012 · CA · contact PI
Cellular Reprogramming by KSHV Latent Genes and miRNAs$291,273
P01 · FY2012 · CA · contact PI
Virogenomics Core$270,710
P01 · FY2012 · CA · contact PI
Regulation of the KSHV Latent Promoter$234,401
R01 · FY2012 · CA · contact PI
Regulation of the KSHV Latent Promoter$64,986
R01 · FY2012 · CA · contact PI
Targeted Therapies for HIV-Associated Kaposi Sarcoma and Lymphoma$305,754
R01 · FY2011 · CA · contact PI
ART Modulation of Viral Pathogenesis in Oral Epithelia$305,055
R01 · FY2011 · DE · contact PI
Cellular Reprogramming by KSHV Latent Genes and miRNAs$291,273
P01 · FY2011 · CA · contact PI
Virogenomics Core$270,710
P01 · FY2011 · CA · contact PI
Regulation of the KSHV Latent Promoter$234,401
R01 · FY2011 · CA · contact PI
ART Modulation of Viral Pathogenesis in Oral Epithelia$314,490
R01 · FY2010 · DE · contact PI
Regulation of the KSHV Latent Promoter$241,650
R01 · FY2010 · CA · contact PI
ART Modulation of Viral Pathogenesis in Oral Epithelia$317,667
R01 · FY2009 · DE · contact PI
ART Modulation of Viral Pathogenesis in Oral Epithelia$317,667
R01 · FY2008 · DE · contact PI
Regulation of the KSHV latent promoter$225,602
R01 · FY2008 · CA · contact PI
ART Modulation of Viral Pathogenesis in Oral Epithelia$321,200
R01 · FY2007 · DE · contact PI
Regulation of the KSHV latent promoter$225,602
R01 · FY2007 · CA · contact PI
Primate Model for Viral Pathogenesis in the Oral Cavity$253,271
R21 · FY2006 · DE · contact PI
Regulation of the KSHV latent promoter$232,340
R01 · FY2006 · CA · contact PI
Regulation of the KSHV latent promoter$100,000
R01 · FY2006 · CA · contact PI
Regulation of the KSHV latent promoter$251,728
R01 · FY2005 · CA
Primate Model for Viral Pathogenesis in the Oral Cavity$153,887
R21 · FY2005 · DE
In situ real-time PCR arrays for viral-associated canc*$73,000
R03 · FY2005 · CA
Regulation of the KSHV latent promoter$237,931
R01 · FY2004 · CA
In situ real-time PCR arrays for viral-associated canc*$65,568
R03 · FY2004 · CA
Real-time high throughput PCR for microbial pathogens$206,766
R21 · FY2003 · CA
Unified high throughput diagnostics$206,230
R21 · FY2003 · EB
Unified high throughput diagnostics$13,520
R21 · FY2003 · EB
Real-time high throughput PCR for microbial pathogens$10,010
R21 · FY2003 · CA
Unified high throughput diagnostics$196,500
R21 · FY2002 · EB
Real-time high throughput PCR for microbial pathogens$184,875
R21 · FY2002 · CA
Human gamma herpes virus DNA vaccines$0
P20 · FY2002 · RR
Human gamma herpes virus DNA vaccines$256,079
P20 · FY2001 · RR
Human gamma herpes virus DNA vaccines$0
P20 · FY2001 · RR
Human gamma herpes virus DNA vaccines$256,079
P20 · FY2000 · RR